This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Solian

Sanofi

Drug Names(s): amisulpride

Description: Amisulpride is a second generation antipsychotic, a substituted benzamide. It is different from other atypical antipsychotics in that it has little affinity other than at dopamine receptors. At low doses (100-150mg per day), it blocks presynatic D3/D2 autoreceptors and acts mainly in the frontal area, which has been postulated to be effective for negative symptoms of schizophrenia. At high doses (400-800gm per day) the drug blocks additionally postsynaptic D3/D2 receptors, reducing dopaminergic activity in the mesolimbic pathway (terminating in the ventral striatum). At this dosage the drug is effective in the treatment of schizophrenia with positive symptoms.

Representative receptor affinities include:
D2: 1.3 nM;
D1: >1000 nM;
D3: 3.2 nM;
D4: >1000 nM;
5HT2A: 2000 nM;
5HT1A: >10,000 nM;
5HT2C: >10000 nM;
alpha-2 adrenergic: 1600 nM;
alpha-1 adrenergic: 7100 nM;
H1: >10000 nM;
M3: >10000 nM.


Solian News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug